Intervention

Tivantinib

ClinicalTrials.gov intervention label

Clinical trials7
Recruiting0
Common conditions21
Lead sponsors shown4

Clinical trials

7 shown
Study of the Combination of Tivantinib Plus Pemetrexed and CarboplatinNCT02049060 · 2013-01-01
COMPLETED
Tivantinib in Treating Patients With Previously Treated Malignant MesotheliomaNCT01861301 · 2013-01-01
TERMINATED
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid TumorsNCT01654965 · 2012-07-24
COMPLETED
Tivantinib in Treating Patients With Recurrent or Metastatic Breast CancerNCT01575522 · 2012-03-01
COMPLETED
Tivantinib in Treating Patients With Metastatic Prostate CancerNCT01519414 · 2012-01-11
COMPLETED
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerNCT01244191 · 2011-01-11
TERMINATED
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) ProtocolsNCT01178411 · 2010-08-31
COMPLETED

Common conditions

Adult Solid Neoplasm1Advanced Solid Tumors1Epithelioid Mesothelioma1Estrogen Receptor Negative1HER2/Neu Negative1Hormone-Resistant Prostate Cancer1Malignant Pleural Mesothelioma1Non Squamous, Non-small-cell Lung Cancer1Nonsquamous Nonsmall Cell Neoplasm of Lung1Progesterone Receptor Negative1Prostate Adenocarcinoma1Recurrent Breast Carcinoma1Recurrent Malignant Mesothelioma1Recurrent Prostate Carcinoma1Sarcomatoid Mesothelioma1Stage II Pleural Mesothelioma1Stage III Pleural Mesothelioma1Stage IV Breast Cancer1Stage IV Pleural Mesothelioma1Stage IV Prostate Cancer1Triple-Negative Breast Carcinoma1

Trial status mix

COMPLETED5
TERMINATED2

Phase mix

PHASE25
PHASE13
PHASE31

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.